MCM
DGX icon

Maple Capital Management’s Quest Diagnostics DGX Stock Holding History

Maple Capital Management’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$490K Hold
2,313
– – 0.03% 78
2026
Q1 		$453K Sell
2,313
-757
-25% -$147K 0.03% 77
2025
Q4 		$533K Buy
+3,070
New +$559K 0.03% 73

Other funds holding DGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Maple Capital Management's DGX Position: Q2 2026 in Review

Maple Capital Management held its Quest Diagnostics (DGX) position steady in Q2 2026 at 2,313 shares worth $490K. The position accounts for 0.03% of the portfolio, ranked #78.

Maple Capital Management first reported a position in DGX in Q4 2025 and has held it in 3 quarters since. The position peaked at $533K in Q4 2025. 1,108 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

  • Maple Capital Management held 2,313 shares of Quest Diagnostics worth $490K as of Q2 2026.
  • Maple Capital Management left its Quest Diagnostics share count unchanged in Q2 2026.
  • Quest Diagnostics made up 0.03% of Maple Capital Management's portfolio in Q2 2026, its #78 holding.
  • Maple Capital Management first reported a position in Quest Diagnostics in Q4 2025 and has held it in 3 quarters since.
  • Maple Capital Management's Quest Diagnostics position peaked at $533K in Q4 2025.
  • 1,108 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Maple Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.